The Zacks Analyst Blog Highlights:DeVry, Synergy Pharmaceuticals, Takeda
Pharmaceutical, Forest Laboratories and Ironwood Pharmaceuticals
CHICAGO, Jan. 2, 2013
CHICAGO, Jan. 2, 2013 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include DeVry, Inc. (NYSE:DV), Synergy
Pharmaceuticals (Nasdaq:SGYP), Takeda Pharmaceutical Company Limited
(OTC:TKPYY), Forest Laboratories Inc. (NYSE:FRX) and Ironwood Pharmaceuticals
Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Monday's Analyst Blog:
DeVry: A Strong Buy
Rising earnings estimates on the back of strong first-quarter fiscal 2013
results, which included a 58.1% earnings surprise, helped this diversified
education provider DeVry, Inc. (NYSE:DV) achieve a Zacks #1 Rank (Strong Buy)
on December 29. This stock turned around from past few quarterly results and
has bright prospects going forward.
The stock is currently trading at 80.9% discount to its 52-week high of
$42.37. With a discounted price and long-term expected earnings growth rate of
9.8%, this stock offers an attractive investment opportunity.
The Rank Drivers
Combination of a solid cost-control strategy, improving new student
enrollments, brand building and growth investments and an upbeat outlook are
the rank drivers for this stock.
On October 25, DeVry reported first-quarter fiscal 2013 (ended September 30)
earnings of 49 cents per share, largely beating the Zacks Consensus Estimate
of 31 cents by 58%. Higher-than-expected cost savings and improving new
student enrollments at several institutions drove the earnings beat.
Continued progress on its performance improvement plan to align costs, regain
enrollment growth and make growth investments helped the company to turnaround
from the past few weak quarterly results.
Revenue of $482.7 million also beat the Zacks Consensus Estimate of $481
million primarily driven by better-than-expected new enrollment growth at the
medical institutions. Though post-secondary enrollments across all its
programs declined year over year, the company witnessed solid new enrollment
growth in healthcare institutions like Chamberlain College of Nursing and
Carrington Colleges. The sequential improvement in new enrollments at DeVry
University is also an encouraging sign.
Operating costs declined both year over year and sequentially owing to DeVry's
cost saving initiatives. Though near-term results are expected to remain
choppy due to continued enrollment declines at the flagship DeVry University,
we believe that the company has a solid plan to reduce costs and drive
attractive earnings growth in the 2014-2016 period.
Pipeline Progress at Synergy Pharma
Synergy Pharmaceuticals (Nasdaq:SGYP) recently initiated a phase IIb study
with plecanatide for the treatment of patients suffering from
constipation-predominant irritable bowel syndrome (IBS-C).
Synergy Pharma will be enrolling 350 patients suffering from IBS-C around 70
sites in the US. These patients will be treated with any one of the four doses
of plecanatide (0.3, 1.0, 3.0, or 9.0 mg) or placebo for 12 weeks.
The trial will be evaluating the average change in complete spontaneous bowel
movements (CSBM's) during the trial period in comparison to their baseline
weekly CSBM rate that was established during the screening phase of the study.
In addition to this, Synergy Pharma will be evaluating spontaneous bowel
movements (SBM's) and daily abdominal pain, discomfort along with bloating
scores and impact of the candidate on disease-specific quality of life
measures during the study.
The IBS-C market already has players like Takeda Pharmaceutical Company
Limited (OTC:TKPYY), Forest Laboratories Inc. (NYSE:FRX) and Ironwood
We note that Synergy Pharma is conducting an independent study on plecanatide
for the treatment of patients suffering from chronic idiopathic constipation.
The company expects to complete the study soon and report top-line results
within a few weeks.
Apart from plecanatide, Synergy Pharma also completed a phase I clinical trial
on SP-333, a guanylate cyclase C (GC-C) agonist, being developed for the
treatment of ulcerative colitis (UC) and other GI diseases. The company now
expects to initiate a multi-dose, dose-escalation trial in patients by January
Synergy Pharma currently carries a Zacks #3 Rank (Hold) in the short run.
Meanwhile, Ironwood Pharma carries a Zacks #2 Rank (Buy).
Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
Zacks Investment Research
800-767-3771 ext. 9339
SOURCE Zacks Investment Research, Inc.
Press spacebar to pause and continue. Press esc to stop.